Overview

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Status:
Recruiting

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Pulmonary Hospital, Shanghai, China

Treatments:

Bevacizumab